Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / F2G Ltd

Clinicaltrial registered26 Oct 2026

F2G Ltd

26 Oct 2026: Trial registered · Managed Access Program Allowing Access to Olorofim. Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
26 Oct 2026
Title
Managed Access Program Allowing Access to Olorofim
Study Type
Expanded Access
Status
Available
Reference
NCT07895264
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at F2G Ltd

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.